Albany Molecular Research Profit Margin

Albany Molecular Research (AMRI) currently reports a profit margin of -8.78% as of June 2017. That compares with -7.37% in the prior-year period — down 19.1% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore Albany Molecular Research's profit margin history and peer comparisons.

Albany Molecular Research's profit margin decreased from -7.37% to -8.78% — a 19.1% year-over-year decrease (period ending June 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albany Molecular Research's profit margin of -8.78% is lower than the its sector sector average of 13.23%. That is roughly 166.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Albany Molecular Research's current -8.78% should be judged against industry norms (sector average: 13.23%) and against AMRI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -8.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for Albany Molecular Research, and consider following AMRI for alerts when major investors trade the stock.